Usama Ahmed Ali, MD
Colon & Rectal Surgery · New York, NYNPI 1700509452
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (45.4%), education and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 88.3% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $3,833, 9.3 times the $413 reported in 2023.
Across 36 payments — averaging $148.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Davol Inc.$207
- BD$199
- Vertex$60
- Integra Lifesciences Corporation$39
- CSL Behring$35
- plus $85 from 4 others
What the payments were for
- Travel & lodging$2,42845%
- Food & beverage$77915%
- Education$2,13640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 27 | $4,718 |
| Davol Inc. | 1 | $207 |
| BD | 1 | $199 |
| Vertex | 1 | $60 |
| Integra Lifesciences Corporation | 1 | $39 |
| CSL Behring | 1 | $35 |
| Ceribell, Inc. | 1 | $28 |
| Merck | 1 | $21 |
| Axonics, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,427
- DAVINCI XI$2,000
- Phasix Mesh$406
How this compares
$5,343 in reported general payments places this provider in the 70th percentile of 177 colon & rectal surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $128 |
| Oxycodone Hcl | 11 | $6 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in New York
- Sanghyun KimNew York$154K
- Mehraneh JafariNew York$50K
- Jeffrey MilsomNew York$42K
- David SchwartzbergNew York$26K
- Richard WhelanNew York$23K
- Alessandro FicheraNew York$20K
- Juliet RayNew York$17K
- Cary AaronsNew York$16K
- Debbie BakesNew York$15K
- Parul ShuklaNew York$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.